On March 30, BullFrog AI signed a commercial agreement with a top 5 global pharmaceutical company by revenue. The agreement utilizes the proprietary bfLEAP® platform to identify and prioritize therapeutic targets for Major Depressive Disorder (MDD). The MDD market was valued at over $8 billion in 2025 and is expected to exceed $11 billion by 2032.
Infinimmune has announced a strategic collaboration with pharmaceutical giant Merck to discover and develop multiple therapeutic antibodies. The agreement is potentially valued at up to $838 million, primarily structured through milestone-based payments tied to successful development and commercialization. Under the…
Read the full storyBullfrog AI Inc. (BFRG) announced a significant commercial agreement with one of the world's top five pharmaceutical companies to advance drug discovery for Major Depressive Disorder (MDD). Under the terms of the deal, the pharmaceutical giant will leverage Bullfrog AI's proprietary bfLEAP® machine-learning platform…
BullFrog AI Holdings, Inc. (NASDAQ: BFRG) has announced a significant commercial agreement with one of the world's top five pharmaceutical companies by revenue. Following the announcement, BullFrog AI shares surged significantly as market participants reacted to the high-profile partnership. Under the terms of the…